Letter from the ECCO President
ECCO President
Dear ECCO Family,
As the final weeks of 2025 unfold, it is a pleasure to welcome you to this last issue of the year on the ECCO website. This time of year naturally invites reflection: on what we have accomplished together and on the shared commitment that continues to drive our community forward.
Our network and its people remain at the heart of ECCO. In this issue, you will find a written interview with JCC Editor-in-Chief Laurent Peyrin-Biroulet, who shares insights into the journal’s mission and its role in advancing excellence in IBD research. A video interview with JCC Plus Associate Editor Vishal Sharma offers further perspective on scientific publishing and editorial collaboration. Also, the “Meet the Reps” video interview from Lithuania highlights national engagement within our organisation.
The Y-ECCO literature reviews, written by three outstanding colleagues, summarises exciting new findings in the IBD field, covering the IL-22–oncostatin M axis, the use of wearable devices to identify and predict disease flares, and infliximab levels and clearance in acute severe ulcerative colitis. The interview with Robin Dart also reflects his leadership as a strong voice for early-career professionals since 2022 and his current role as Chair of the Y-ECCO Committee.
This edition also includes thoughtful articles on the importance of research in holistic care in IBD, as well as a comprehensive overview of paediatric IBD that covers epidemiology, diagnosis, classification, and histological features, highlighting the value of research-driven, patient-centred care across all stages of life.
Education and innovation remain central to ECCO’s mission. A letter from the e-learning Editor-in-chief Pascal Juillerat reflects our ongoing commitment to high-quality digital education. We are also pleased to announce the launch of the new Congress platform, which introduces transcription and AI-powered translation features in multiple languages. These tools are designed to make scientific content more accessible and to enhance engagement across our global IBD community.
As the year comes to an end, we once again remember Professor Brian Feagan and honour his outstanding contributions to IBD research and their lasting impact on our field.
Finally, I would like to sincerely thank everyone who has contributed to ECCO’s activities throughout 2025, including our authors, editors, committee members, and the ECCO Office, for their dedication and collaboration.
I wish you a peaceful end of the year with your loved ones, and I very much hope to see you all at ECCO 2026 in Stockholm, as we carry our shared work forward into the new year.
With warm regards,
Fernando Magro